TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07828860: Safety and Efficacy of Soquelitinib in Adults With Hidradenitis Suppurativa

Sponsor: Corvus Pharmaceuticals, Inc. · Phase: PHASE1 · Area: DERMATOLOGY_AESTHETIC · Target Enrollment: 25 pts

Competing Trials Overlap

8 Active Trials

Excess Burn Exposure

$771,936

Rescue Site Savings

+$508,776

Unlock Full NCT07828860 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07828860 Rescue Dossier →